April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Six months study on signs and symptoms of polyquad preserved travoprost/timolol fixed combination on previously treated glaucoma patients.
Author Affiliations & Notes
  • Teresa Rolle
    Department of Surgical Sciences- Eye Clinic, University of Torino, Torino, Italy
  • Rachele R Penna
    Department of Surgical Sciences- Eye Clinic, University of Torino, Torino, Italy
  • Laura Dallorto
    Department of Surgical Sciences- Eye Clinic, University of Torino, Torino, Italy
  • Fiamma Campana
    Unità Complessa di Oculistica, Presidio Ospedaliero S. Croce e Carle, Cuneo, Italy
  • Luigia Scudeller
    IRCCS Policlinico San Matteo, Clinical Epidemiology and Biometric Unit, Scientific Direction, Pavia, Italy
  • Sara Lanteri
    IRCCS Policlinico San Matteo-Eye Clinic, University of Pavia, Pavia, Italy
  • Gemma C Rossi
    IRCCS Policlinico San Matteo-Eye Clinic, University of Pavia, Pavia, Italy
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2916. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Teresa Rolle, Rachele R Penna, Laura Dallorto, Fiamma Campana, Luigia Scudeller, Sara Lanteri, Gemma C Rossi; Six months study on signs and symptoms of polyquad preserved travoprost/timolol fixed combination on previously treated glaucoma patients.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2916.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To assess usefulness and tolerability of switching glaucoma patients to the fixed combination Travoprost 0.004%/Timolol 0.5% with polyquad (PQ-TTFC); to record effects on tear film break-up time (TF-BUT) and on quality of life (OSDI).

Methods: Multicenter, observational cohort, 6 month study. 50 patients on concomitant Timolol 0.5% (twice a day) and Dorzolamide (twice a day) or Timolol and Latanoptost (once a day) (BAK-preserved) were switched to PQ-TTFC (evening dosage). IOP, TFBUT and AEs were recorded and all patients completed the OSDI questionnaire at baseline and after 6 months. All analysis refers to right eye; left eye’s data are similar.

Results: Median age was 70 [63-73] years, women were 54.9% of the sample. IOP significantly decreased (from 18 [16-21] to 15 [12-17] mmHg) after substitution (p<0,001). At baseline 31.4% of patients presented an IOP <18mmHg, the percentage increased to 80% of subjects at 6 months (p<0.001). TF-BUT improved of 2.7±1.9 sec (from 7 [5-8] to 10 [9-11] sec, p<0.001). Only one patient discontinued the new therapy due to periocular skin pigmentation. Quality of life improved from 28 (moderate) to 19 (mild) (p<0.001).

Conclusions: PQ-TTFC appeared useful in this selected population: patients who underwent a regimen modification to PQ-TTFC obtained further reduction in IOP; improvement in ocular surface status with no exposition to BAK toxicity; and reported a better quality of life perception. The low discontinuation’s rate at 6 months indicates a good tolerability profile.

Keywords: 568 intraocular pressure • 503 drug toxicity/drug effects • 669 quality of life  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×